A poorly characterized protein, historically thought to be a chaperon or enzyme, may actually be a key player in prostate ...

It must be aggressive enough to fight infections and cancer, yet restrained enough to avoid attacking the body's own tissues.

In this interview conducted at SLAS EU 2023 in Brussels, Belgium, we spoke to Ulrike Künzel, Associate Director in the Functional Genomics department at AstraZeneca, about the application of arrayed ...

An artistic rendering of CRISPR-enhanced T-cells attacking a tumor. Research has shown that the gene-editing system CRISPR can modulate T cell behavior to make them better cancer killers without ...

CRISPR/Cas9 gene editing has made possible a multitude of biomedical experiments including studies that systematically turn off genes in cancer cells to look for ones that the cancer cells heavily ...

Horizon Discovery Group plc (LSE: HZD) (“Horizon” or “the Company”), a global leader in gene editing and gene modulation technologies, today announced the extension of its CRISPR Screening Service to ...

A research team from the University of Osaka, in collaboration with the Massachusetts Institute of Technology, has uncovered ...

In a 15-patient, Phase 1, first-in-human trial, a one-time CRISPR-Cas9 gene-editing therapy safely reduced LDL cholesterol ...

CRISPR stocks are high risk but hold potential for aggressive investors. CRISPR Therapeutics and its partner Vertex Pharmaceuticals have the only approved CRISPR therapy. Several other biotech ...